Skip to main content Help with accessibility Skip to main navigation

January 2022 updates to the website

The website has now been updated following January's LSCMMG

The following guidelines have been added/updated:

Rheumatoid Arthritis High Cost Drugs pathway - updated

Guidelines for the prescribing of nutritional supplements post bariatric surgery - updated

Inclisiran TA 733 position statement - new

The following Items have been updated and added to the website following the latest Strategic Commissioning Committee (SCC) Meeting:

Inclisiran - treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA733)

Upadacitinib - treating moderate rheumatoid arthritis (NICE TA744)

Glycopyrronium oral - hypersalivation in adults and children (non-Parkinson’s disease)

Clonidine 25 mcg tablets - Vasomotor symptoms (VMS) associated with menopause

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Cenobamate - treating focal onset seizures in epilepsy (NICE TA753)

Trixeo Aerosphere - a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist

Bevespi Aerosphere - a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)